Our product line is led by Enduracaine™, an ultra–long-acting, low-toxicity local anesthetic designed to transform post-operative pain management.

Enduracaine™ is a novel combination of three well-established and highly safe anesthetic agents. This unique formulation provides superior pain control where other approaches—such as bupivacaine products—have consistently fallen short.

The drug is formulated as an aqueous solution containing 0.4% lidocaine, 0.2% tetracaine, and 4 mcg/mL of epinephrine, delivering both extended duration and a favorable safety profile.

Ventis Pharma is currently advancing Enduracaine™ through the FDA fast-track approval process. While awaiting final approval, we plan to introduce an intermediate off-label 503B iteration to meet immediate clinical needs. Following this, the fully optimized, user-friendly version will be launched. In parallel, we are developing a low-dose oral analgesic to expand our pain management portfolio in the dental arena.

Beyond Enduracaine™, Ventis Pharma is actively researching moderate-cost adjuvants that enhance the effectiveness of local anesthetics across multiple indications. The recent consensus from the American Society of Anesthesiologists—published in Anesthesiology—highlighted the lack of efficacy in bupivacaine products. This underscores the urgent market need for safer, more effective alternatives like ours.

While several other drugs in the FDA pipeline claim extended anesthetic duration, they rely on bupivacaine, a drug with a well-documented history of cardiovascular risks. Some even combine bupivacaine with a non-steroidal anti-inflammatory agent previously withdrawn from the market for safety concerns, compounding the risk.

Enduracaine™ eliminates these concerns by offering a safer, more effective, and truly differentiated formula—representing the future of non-opioid pain management.